AbCellera Biologics Inc.ABCLEarnings & Financial Report
AbCellera Biologics Inc. is a Vancouver, British Columbia-based biotechnology company that discovers and develops antibody therapeutics. The company is best known for its leading role in the Pandemic Prevention Platform, a project of DARPA's Biological Technologies Office. AbCellera utilizes a proprietary technology platform, which they claim can develop "medical countermeasures within 60 days." Its platform for single-cell screening was initially developed at the University of British Columbia.
ABCL Q3 2025 Key Financial Metrics
Revenue
$9.0M
Gross Profit
N/A
Operating Profit
$-76.3M
Net Profit
$-57.1M
Gross Margin
N/A
Operating Margin
-851.8%
Net Margin
-637.8%
YoY Growth
37.6%
EPS
$-0.19
Financial Flow
AbCellera Biologics Inc. Q3 2025 Financial Summary
AbCellera Biologics Inc. reported revenue of $9.0M for Q3 2025, with a net profit of $-57.1M (-637.8% margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $9.0M |
|---|---|
| Net Profit | $-57.1M |
| Gross Margin | N/A |
| Operating Margin | -851.8% |
| Report Period | Q3 2025 |
AbCellera Biologics Inc. Annual Revenue by Year
AbCellera Biologics Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $28.8M).
| Year | Annual Revenue |
|---|---|
| 2024 | $28.8M |
| 2023 | $38.0M |
| 2022 | $485.4M |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $9.2M | $10.0M | $7.3M | $6.5M | $5.0M | $4.2M | $17.1M | $9.0M |
| YoY Growth | -57.4% | -18.4% | -27.2% | -1.4% | -45.0% | -57.5% | 133.3% | 37.6% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $1.49B | $1.46B | $1.41B | $1.39B | $1.36B | $1.34B | $1.40B | $1.36B |
| Liabilities | $335.8M | $333.2M | $301.5M | $314.7M | $304.5M | $321.2M | $395.0M | $392.0M |
| Equity | $1.15B | $1.13B | $1.11B | $1.08B | $1.06B | $1.02B | $1.01B | $964.0M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-19.6M | $-41.7M | $-30.0M | $-28.9M | $-8.0M | $-11.6M | $-32.4M | $-52.6M |
More Companies
ILMN
ILLUMINA, INC.
Revenue
$1.2B
Net Profit
$334.0M
UTHR
UNITED THERAPEUTICS Corp
Revenue
$799.5M
Net Profit
$338.7M
GMAB
GENMAB A/S
Revenue
$925.0M
Net Profit
$336.0M
GH
Guardant Health, Inc.
Revenue
$265.2M
Net Profit
$-92.7M
NBIX
NEUROCRINE BIOSCIENCES INC
Revenue
$805.5M
Net Profit
$153.7M
EXEL
EXELIXIS, INC.
Revenue
$598.7M
Net Profit
$244.5M
MDGL
MADRIGAL PHARMACEUTICALS, INC.
Revenue
$287.3M
Net Profit
$-114.2M
QGEN
QIAGEN N.V.
BMRN
BIOMARIN PHARMACEUTICAL INC
Revenue
$776.1M
Net Profit
$-30.7M
ARWR
ARROWHEAD PHARMACEUTICALS, INC.
Revenue
$264.0M
Net Profit
$30.8M